– PDUFA target action date of June 30, 2026 – – Priority Review designation is granted to applications for drugs that, if approved, would be a significant improvement in the safety or effectiveness of treating a serious condition – – Veligrotug now has both Priority Review and Breakthrough Therapy Designations, each following requests which included … [Read more…]
CADEMPINO, Switzerland–(BUSINESS WIRE)–#ClinicalTrial—Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase … [Read more…]
MARSEILLE, France–(BUSINESS WIRE)–#immunotherapy–Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well … [Read more…]
WASHINGTON–(BUSINESS WIRE)–#congress–Today, Council for Citizens Against Government Waste (CCAGW) President Tom Schatz issued the following statement in response to the announcement of two proposed Center for Medicare and Medicaid Innovation (CMMI) models, “GLOBE” and “GUARD,” that seek to advance so-called ‘most favored nation’ (MFN) drug price controls: “CCAGW is disappointed to see the administration push … [Read more…]
TORONTO–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today announced that it will voluntarily transfer its U.S. stock exchange listing to the Nasdaq Global Market (“Nasdaq”) from the NYSE American LLC (“NYSE American”). The Company expects that its common shares … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “ENT Disorder Treatment Market – Global Forecast 2025-2032” report has been added to ResearchAndMarkets.com’s offering. The ENT disorder treatment market is experiencing rapid transformation as organizations adopt new medical technologies and evolving care models to address complex clinical and operational challenges. Senior decision-makers are seeking strategies that enable both enhanced patient outcomes and … [Read more…]
Urges Board to Allow Shareholders to Have Their Final Say on This Ill-Conceived Transaction NEW YORK–(BUSINESS WIRE)–Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which together own 30.2% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today responded to the fourth postponement of STAAR’s Special Meeting of … [Read more…]
CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced the U.S. launch of the next generation LifeVest® wearable cardioverter defibrillator (WCD). This marks the fifth FDA-approved LifeVest WCD, which works seamlessly with the recently launched next generation LifeVest WCD garment, the most comfortable LifeVest WCD ever.1 Backed by … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “MBA Strategic Thinking for Pharma and Biopharma Professionals Training Course (Feb 23rd – Feb 24th, 2026)” training has been added to ResearchAndMarkets.com’s offering. Working in the highly competitive pharmaceutical industry, with ever-increasing change and pressure, is probably one of the most challenging managerial roles of any industry today. This MBA strategic thinking workshop … [Read more…]
MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announced today that it will participate in the 44th Annual J.P. Morgan Healthcare Conference, San Francisco, USA, to be held on January … [Read more…]
